S 2397 – Massachusetts

Status: Inactive / Dead
Year Introduced: 2019
Link: https://malegislature.gov/Bills/191/S2397

Relative to pharmaceutical access, costs and transparency. A pharmaceutical manufacturing company shall provide early notice to the commission if it plans to increase the wholesale acquisition cost of a: (i) brand-name drug by more than 20 per cent per wholesale acquisition cost unit during any 12-month period; or (ii) generic drug priced at $100 or more per wholesale acquisition cost unit by 200 per cent or more during any 12-month period.


Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found